Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date Filed: May 13, 2005
Reporting Period: Three months ended March 31, 2005
Context: This filing serves to disseminate a press release (Exhibit 99.1) containing the company's financial results for the first quarter of 2005. The press release is furnished under Item 2.02 but is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain the actual financial data. Specific values for revenue, profit, cash flow, margins, debt, or liquidity are not present in this document; they are contained within the attached Exhibit 99.1 (Press Release), which is not included in the input text.
Material Changes
The filing text does not provide specific data to compare against prior periods. It only confirms that results for the three months ended March 31, 2005, were reported via press release.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items, if present, would be located in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Locate and review Exhibit 99.1 (Press Release dated May 13, 2005) to obtain actual financial figures.
- Verify the specific revenue and net loss figures for the quarter ended March 31, 2005.
- Check the press release for updates on clinical trial progress or product development milestones.
- Confirm cash position and burn rate details not included in this summary.